- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | NEJM nejm.org
- ESMO 2023: LITESPARK-005 Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3 UroToday
- ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes Yahoo Finance
- At ESMO, Merck touts Welireg’s potential in kidney cancer FiercePharma
- ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma UroToday
- View Full Coverage on Google News
Tag Archives: Metastatic
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma – PR Newswire
- Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma PR Newswire
- Delcath Systems (NASDAQ:DCTH) Skyrockets on FDA Approval for Hepzato Liver Therapy – TipRanks.com TipRanks
- Delcath Systems Stock Is Rocketing Higher: What’s Going On? – Delcath Systems (NASDAQ:DCTH) Benzinga
- Why Is Delcath Systems (DCTH) Stock Up 72% Today? InvestorPlace
- Persistence pays for Delcath as cancer treatment Hepzato Kit finally scores FDA nod FiercePharma
- View Full Coverage on Google News
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb
- Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial Bristol-Myers Squibb
- Bristol Myers’ Opdivo stages comeback in bladder cancer, teeing up 2 ‘Merck’ showdowns FiercePharma
- Bristol Myers’ Opdivo extends survival in bladder cancer study Reuters
- First-line Nivolumab Plus Chemo Provides Survival Benefit in Metastatic Urothelial Carcinoma OncLive
- Study: Bladder Cancer Drug Extends Survival Newsmax
Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer – Neuroscience News
- Promising Phase 2 Trial Results for Pembrolizumab in Metastatic Brain Cancer Neuroscience News
- Study of immunotherapy for brain cancer metastases shows promising results News-Medical.Net
- Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas Science
- New Weapon Against Brain Cancer: Gene Engineered Cell Therapy’s Two-Pronged Assault on Metastatic Melanomas SciTechDaily
- Scientists develop new immuno-therapeutic approach to target brain metastatic melanomas News-Medical.Net
- View Full Coverage on Google News
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) – Yahoo Finance
- G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) Yahoo Finance
- GTHX stock falls on decision to halt colorectal cancer trial (NASDAQ:GTHX) Seeking Alpha
- Pharma Stock Hits Record Low Due to Pulled Study Schaeffers Research
- G1 Therapeutics to halt drug trial in colon cancer, shares plunge Reuters.com
- Cosela/Immunochemotherapy Trial for Colorectal Cancer Stopped for Limited Anti-Tumor Efficacy Data Curetoday.com
- View Full Coverage on Google News
Mother-of-three dies nine days after Stage Four Metastatic Melanoma diagnosis
Elizabeth was told she had kidney stones, but nine days after doctors found the real reason for the 39-year-old mum-of-three’s pain she was dead
- Mother-of-three died nine days after she was diagnosed with aggressive cancer
- Elizabeth Kelly believed she was suffering from kidney stones so visited doctor
- She was diagnosed with cancer and died nine days after receiving the news
A mother-of-three has died just nine days after being diagnosed with an aggressive cancer that was initially believed to be kidney stones.
Elizabeth Kelly, 39, began to suffer from severe pain and believed it had something to do with her kidney when she visited the doctor on December 6.
Doctors diagnosed her with Stage Four Metastatic Melanoma after finding cancer in her lungs, breast and spine before it quickly spread to her brain and bones as well.
A mother-of-three has died just nine days after being diagnosed with an aggressive cancer that was initially believed to be kidney stones
Her partner AJ was left without a wife and their three children Sienna, 7, and twins Fletcher and Scarlett, 5, without a mother when Ms Kelly then died on December 15.
Close family friend Russell Spear said Ms Kelly had fought against the cancer as well as she could have and had been on treatment for four days before she died.
‘It gave them time to throw some punches back at this thing but unfortunately the cancer was too severe and her body couldn’t handle it,’ he told Yahoo News.
Mr Spear has kickstarted a GoFundMe to help raise money for the devastated family.
‘Words can’t describe the impact of the loss of such an incredible woman,’ he wrote.
‘Grief isn’t a strong enough word for what we feel, but we grieve for the loss of a daughter, a wife, a mum and a friend, and for those three little kids who will now have their mum only in their memories, hearts and when they see the stars in the sky.’
Mr Spear said the money would reduce the financial burden on the family so they could grieve the loss of their loved one.
‘Liz didn’t even get a chance to fight this so we are asking our friends to help AJ and the kids fight everything that comes next,’ he wrote.
Elizabeth Kelly, 39, began to suffer from severe pain and believed it had something to do with her kidney when she visited the doctor on December 6
‘To navigate their way through this tremendously difficult time without the financial stress.
‘Allowing AJ, Sienna, Fletcher and Scarlett to focus on their grief and healing as a family.’
Mr Spear said the family was ‘reluctant’ to ask for help and he had taken it upon himself to help raise the money.
‘To support and give our friend and his 3 cheeky kids the breathing space to care for each other after the most unfair and heartbreaking of events,’ he wrote.
‘All monies raised will go directly to AJ as he supports his family through the harrowing next chapter.’
This Activity Can Reduce the Risk of Metastatic Cancer by 72%
The researchers discovered that high-intensity aerobic exercise increased the consumption of glucose reducing the amount of energy available to the tumor.
Exercise defeats cancer by increasing glucose consumption.
According to recent Tel Aviv University research, aerobic exercise can significantly lower the chance of developing metastatic cancer by 72%. The researchers found that high-intensity aerobic exercise increased internal organs’ consumption of glucose (sugar), decreasing the amount of energy available to the tumor.
Professor Carmit Levy. Credit: Tel Aviv University
Professor Carmit Levy from the Department of Human Genetics and Biochemistry and Dr. Yftach Gepner from the School of Public Health and the Sylvan Adams Sports Institute at TAU’s Sackler Faculty of Medicine conducted the study. Prof. Levy notes that the new research has resulted in a very important discovery by merging scientific know-how from different schools at TAU, which may help avoid metastatic cancer, Israel’s top cause of death. The study was recently published on the cover of the journal of Cancer Research.
Prof. Levy and Dr. Gepner: “Studies have demonstrated that physical exercise reduces the risk for some types of cancer by up to 35%. This positive effect is similar to the impact of exercise on other conditions, such as heart disease and diabetes. In this study we added new insight, showing that high-intensity aerobic exercise, which derives its energy from sugar, can reduce the risk of metastatic cancer by as much as 72%. If so far the general message to the public has been ‘be active, be healthy’, now we can explain how aerobic activity can maximize the prevention of the most aggressive and metastatic types of cancer.”
The research combined an animal model in which mice were trained under a strict exercise routine with data from healthy human volunteers who were evaluated before and after running. The human data, obtained from an epidemiological study that monitored 3,000 individuals for about 20 years, indicated 72% less metastatic cancer in participants who reported regular aerobic activity at high intensity, compared to those who did not engage in physical exercise.
The animal model exhibited a similar outcome, also enabling the researchers to identify its underlying mechanism. Sampling the internal organs of the physically fit animals, before and after physical exercise, and also following the injection of cancer, they found that aerobic activity significantly reduced the development of metastatic tumors in the lymph nodes, lungs, and liver. The researchers hypothesized that in both humans and model animals, this favorable outcome is related to the enhanced rate of glucose consumption induced by exercise.
Prof. Levy: “Our study is the first to investigate the impact of exercise on the internal organs in which metastases usually develop, like the lungs, liver, and lymph nodes. Examining the cells of these organs we found a rise in the number of glucose receptors during high-intensity aerobic activity – increasing glucose intake and turning the organs into effective energy-consumption machines, very much like the muscles.”
Dr. Yftach Gepner. Credit: Tel Aviv University
She continues, “We assume that this happens because the organs must compete for sugar resources with the muscles, known to burn large quantities of glucose during physical exercise. Consequently, if cancer develops, the fierce competition over glucose reduces the availability of energy that is critical to metastasis. Moreover, when a person exercises regularly, this condition becomes permanent: the tissues of internal organs change and become similar to muscle tissue. We all know that sports and physical exercise are good for our health. Our study, examining the internal organs, discovered that exercise changes the whole body so that the cancer cannot spread, and the primary tumor also shrinks in size.”
Dr. Gepner adds: “Our results indicate that unlike fat-burning exercise, which is relatively moderate, it is a high-intensity aerobic activity that helps in cancer prevention. If the optimal intensity range for burning fat is 65-70% of the maximum pulse rate, sugar burning requires 80-85% – even if only for brief intervals. For example, a one-minute sprint followed by walking, then another sprint. In the past, such intervals were mostly typical of athletes’ training regimens, but today we also see them in other exercise routines, such as heart and lung rehabilitation. Our results suggest that healthy individuals should also include high-intensity components in their fitness programs.”
He concludes, “We believe that future studies will enable personalized medicine for preventing specific cancers, with physicians reviewing family histories to recommend the right kind of physical activity. It must be emphasized that physical exercise, with its unique metabolic and physiological effects, exhibits a higher level of cancer prevention than any medication or medical intervention to date.”
Reference: “An Exercise-Induced Metabolic Shield in Distant Organs Blocks Cancer Progression and Metastatic Dissemination” by Danna Sheinboim, Shivang Parikh, Paulee Manich, Irit Markus, Sapir Dahan, Roma Parikh, Elisa Stubbs, Gali Cohen, Valentina Zemser-Werner, Rachel E. Bell, Sara Arciniegas Ruiz, Ruth Percik, Ronen Brenner, Stav Leibou, Hananya Vaknine, Gali Arad, Yariv Gerber, Lital Keinan-Boker, Tal Shimony, Lior Bikovski, Nir Goldstein, Keren Constantini, Sapir Labes, Shimonov Mordechai, Hila Doron, Ariel Lonescu, Tamar Ziv, Eran Nizri, Guy Choshen, Hagit Eldar-Finkelman, Yuval Tabach, Aharon Helman, Shamgar Ben-Eliyahu, Neta Erez, Eran Perlson, Tamar Geiger, Danny Ben-Zvi, Mehdi Khaled, Yftach Gepner and Carmit Levy, 15 November 2022, Cancer Research.
DOI: 10.1158/0008-5472.CAN-22-0237
Aerobic Activity Can Reduce the Risk of Metastatic Cancer by 72%
Summary: Aerobic exercise reduces the risk of metastatic cancer by elevating glucose consumption.
Source: Tel-Aviv University
A new study at Tel Aviv University found that aerobic exercise can reduce the risk of metastatic cancer by 72%.
According to the researchers, intensity aerobic exercise increases the glucose (sugar) consumption of internal organs, thereby reducing the availability of energy to the tumor.
The study was led by two researchers from TAU’s Sackler Faculty of Medicine: Prof. Carmit Levy from the Department of Human Genetics and Biochemistry and Dr. Yftach Gepner from the School of Public Health and the Sylvan Adams Sports Institute. Prof. Levy emphasizes that by combining scientific knowhow from different schools at TAU, the new study has led to a very important discovery which may help prevent metastatic cancer – the leading cause of death in Israel.
The paper was published in the prestigious journal Cancer Research and chosen for the cover of the November 2022 issue.
Prof. Levy and Dr. Gepner: “Studies have demonstrated that physical exercise reduces the risk for some types of cancer by up to 35%. This positive effect is similar to the impact of exercise on other conditions, such as heart disease and diabetes. In this study we added new insight, showing that high-intensity aerobic exercise, which derives its energy from sugar, can reduce the risk of metastatic cancer by as much as 72%.
“If so far the general message to the public has been ‘be active, be healthy’, now we can explain how aerobic activity can maximize the prevention of the most aggressive and metastatic types of cancer.”
The study combined an animal model in which mice were trained under a strict exercise regimen, with data from healthy human volunteers examined before and after running.
The human data, obtained from an epidemiological study that monitored 3,000 individuals for about 20 years, indicated 72% less metastatic cancer in participants who reported regular aerobic activity at high intensity, compared to those who did not engage in physical exercise.
The animal model exhibited a similar outcome, also enabling the researchers to identify its underlying mechanism. Sampling the internal organs of the physically fit animals, before and after physical exercise, and also following the injection of cancer, they found that aerobic activity significantly reduced the development of metastatic tumors in the lymph nodes, lungs, and liver.
The researchers hypothesized that in both humans and model animals, this favorable outcome is related to the enhanced rate of glucose consumption induced by exercise.
Prof. Levy: “Our study is the first to investigate the impact of exercise on the internal organs in which metastases usually develop, like the lungs, liver, and lymph nodes.
“Examining the cells of these organs we found a rise in the number of glucose receptors during high-intensity aerobic activity – increasing glucose intake and turning the organs into effective energy-consumption machines, very much like the muscles.
“We assume that this happens because the organs must compete for sugar resources with the muscles, known to burn large quantities of glucose during physical exercise.
“Consequently, if cancer develops, the fierce competition over glucose reduces the availability of energy that is critical to metastasis. Moreover, when a person exercises regularly, this condition becomes permanent: the tissues of internal organs change and become similar to muscle tissue. We all know that sports and physical exercise are good for our health.
“Our study, examining the internal organs, discovered that exercise changes the whole body, so that the cancer cannot spread, and the primary tumor also shrinks in size.”
Dr. Gepner adds: “Our results indicate that unlike fat-burning exercise, which is relatively moderate, it is a high-intensity aerobic activity that helps in cancer prevention. If the optimal intensity range for burning fat is 65-70% of the maximum pulse rate, sugar burning requires 80-85% – even if only for brief intervals.
“For example: a one-minute sprint followed by walking, then another sprint. In the past, such intervals were mostly typical of athletes’ training regimens, but today we also see them in other exercise routines, such as heart and lung rehabilitation.
“Our results suggest that healthy individuals should also include high-intensity components in their fitness programs. We believe that future studies will enable personalized medicine for preventing specific cancers, with physicians reviewing family histories to recommend the right kind of physical activity.
“It must be emphasized that physical exercise, with its unique metabolic and physiological effects, exhibits a higher level of cancer prevention than any medication or medical intervention to date.”
About this cancer and exercise research news
Author: Noga Shahar
Source: Tel-Aviv University
Contact: Noga Shahar – Tel-Aviv University
Image: The image is in the public domain
See also
Original Research: Closed access.
“An exercise-induced metabolic shield in distant organs blocks cancer progression and metastatic dissemination” by Carmit Levy et al. Cancer Research
Abstract
An exercise-induced metabolic shield in distant organs blocks cancer progression and metastatic dissemination
Exercise prevents cancer incidence and recurrence, yet the underlying mechanism behind this relationship remains mostly unknown.
Here we report that exercise induces metabolic reprogramming of internal organs that increases nutrient demand and protects against metastatic colonization by limiting nutrient availability to the tumor, generating an exercise-induced metabolic shield.
Proteomic and ex vivo metabolic capacity analyses of murine internal organs revealed that exercise induces catabolic processes, glucose uptake, mitochondrial activity, and GLUT expression. Proteomic analysis of routinely active human subject plasma demonstrated increased carbohydrate utilization following exercise.
Epidemiological data from a 20-year prospective study of a large human cohort of initially cancer-free participants revealed that exercise prior to cancer initiation had a modest impact on cancer incidence in low metastatic stages but significantly reduced the likelihood of highly metastatic cancer.
In three models of melanoma in mice, exercise prior to cancer injection significantly protected against metastases in distant organs.
The protective effects of exercise were dependent on mTOR activity, and inhibition of the mTOR pathway with rapamycin treatment ex vivo reversed the exercise-induced metabolic shield. Under limited glucose conditions, active stroma consumed significantly more glucose at the expense of the tumor.
Collectively, these data suggest a clash between the metabolic plasticity of cancer and exercise-induced metabolic reprogramming of the stroma, raising an opportunity to block metastasis by challenging the metabolic needs of the tumor.
Scientists find novel cell based therapy to treat metastatic melanoma
Researchers have discovered a new treatment for advanced melanoma during the Phase 3 clinical trial. They claim that it is far more effective than the existing leading therapy for metastatic melanoma.
The scientists at the Netherlands Cancer Institute said that the new treatment uses a patient’s own immune cells to fight cancer, and added that its therapy is similar to another type of treatment that has proven to be highly effective for blood cancers, called CAR-T therapy.
Under CAR-T therapy, patients’ T-cells are harvested and modified in the lab into cancer fighters. These modified cells are then infused back into the patient.
Similarly in the melanoma trial, the researchers used an approach called TIL therapy, which involves harvesting a patient’s immune cells—tumour-infiltrating lymphocytes, which are taken from the tumour.
But instead of modifying these tumour cells in the lab like the CAR-T therapy, they’re simply amplified to produce billions of immune cells.
Those amplified immune cells are then injected back into the patient’s blood, where they work to kill the cancer.
Dr John Haanen, a medical oncologist at the Netherlands Cancer Institute, who led the new clinical trial, told NBC News, “We expand them from a million cells to several billion cells.”
The results of the trial were presented at the ESMO Congress 2022 meeting in Paris on Saturday.
To base their hypothesis, the doctors conducted a random trail and assigned 168 patients with metastatic melanoma to receive either TIL treatment or the current standard treatment—an immunotherapy drug called ipilimumab.
Ipilimumab treatment is used in people who don’t respond to a first-line treatment called anti-PD-1 therapy. Notably, all of the patients in the trial had not responded to that treatment.
After observing for three years, the scientists found that people on TIL therapy had a 50% reduction in disease progression and death compared to those who were treated with ipilimumab.
20 per cent of people on TIL therapy saw their tumours disappear completely, compared to 7 per cent in the ipilimumab group.
Though they are still being observed, the median survival time of cancer patients who received TIL therapy was found to be over two years, compared to just over 1.5 years on ipilimumab therapy, researchers found.
(With inputs from agencies)
WATCH WION LIVE HERE
Gilead’s Trodelvy scores ‘surprise’ OS win in metastatic breast cancer, but data will wait for an upcoming conference – Endpoints News
Gilead Sciences said Monday morning that Trodelvy is the first TROP-2 directed ADC to show statistically significant and “clinically meaningful” results in overall survival from a second interim analysis of a Phase 3 trial in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemo.
The announcement surprised Wall St analysts after Gilead unveiled less than stellar OS results after the first interim analysis at ASCO in June. But now, Gilead said it submitted an sBLA to FDA for this new breast cancer indication, but it also said it won’t present the actual OS data from the second interim analysis until an unidentified upcoming medical conference.
Merdad Parsey
“These survival results from the TROPiCS-02 study are important for the breast cancer community and we are encouraged by the potential this may have in helping patients who otherwise have limited alternatives,” said Merdad Parsey, CMO of Gilead, in a statement. “We look forward to discussing these results with global health authorities, as pre-treated HR+/HER2- metastatic disease patients currently have limited treatment options and poor quality of life.”
Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common type of breast cancer and accounts for approximately 70% of all new cases, or nearly 400,000 diagnoses worldwide each year. But almost 1 in 3 cases of early-stage breast cancer become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%, according to Gilead.
Analysts with SVB Securities added that “We expect FDA to approve Trodelvy for HR+/HER2- mBC, but we need to see OS data to assess its competitive profile vs. AZN’s (OP, Berens) Enhertu.”
RBC Capital Markets said in an investor note that most investors had written off the results for Trodelvy in this indication after PFS data came in “positive but with uncertain clinical meaningfulness back in March,” adding today:
This morning’s announcement that TROPiCS-02 showed statistically significant, and reportedly clinically meaningful, OS benefits in a second interim analysis GILD has taken of the trial for oncology drug Trodelvy in a key metastatic breast cancer indication, is a surprise win for the company, as we believe the market had mostly written off the drug in this indication.
OS at the first interim analysis was 13.9 months for Trodelvy, compared with 12.3 months for chemo, RBC analysts also noted, adding that the difference was “likely short of the bar for clinical meaningfulness at that point.”
Trodelvy sales in 2021 totaled $380 million for Gilead, as the company said it saw continued uptake for the approved treatment in second-line metastatic triple-negative breast cancer in the US and Europe, as well as second-line metastatic urothelial cancer in the US.
Sales have since surged higher in 2022, which is welcome news for the company after Gilead took a $2.7 billion writedown last quarter for Trodelvy on the heels of another vague pivotal readout.
The pharma company drew harsh reviews from analysts back in March when it revealed that Trodelvy met its primary endpoint of progression-free survival in late-line metastatic HR+/HER2- breast cancer, but didn’t share the hard data.